


FIGURE 1B




FIGURE 1D




FIGURE 1A




FIGURE 1C

FIGURE 1




FIGURE 1E

FIGURE 1F




FIGURE 1G




FIGURE 1H

FIGURE 1
(CONTD.)

FIGURE 2



Tumor volume (mm³)
300
250
200
150
100
50
0
0
10
20
30
40
50
60
Day after start of treatment
Bev & 19k
Bev & Ang
Bev & Buffer
Bev & Endo
PBS & 19k
PBS & Ang
PBS & Buffer

FIGURE 3



Progression free survival (percent)
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
Day after start of treatment
Bev & 19k
Bev & Ang
Bev & Buffer
Bev & Endo
PBS & 19k
PBS & Ang
PBS & Buffer
PBS & Endo

FIGURE 4

FIGURE 4A

PBS & Buffer




FIGURE 4B

Bev & Buffer




FIGURE 4 (CONTD.)

FIGURE 4C

PBS & Ang




FIGURE 4D

Bev & Ang




FIGURE 4 (CONTD.)

FIGURE 4E

PBS & Endo




FIGURE 4F

Bev & Endo




FIGURE 4 (CONTD.)

FIGURE 4G




FIGURE 4H




FIGURE 5



Tumor volume (mm³)
300
250
200
150
100
50
0
0
10
20
30
40
50
60
Day after start of treatment
Bev & 19k
Bev & 19k
Bev & Ang
Bev & Buffer
Bev & Endo
PBS & 19k
PBS & Ang
PBS & Buffer
PBS & Endo

FIGURE 6



Progression free survival (percent)
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
Day after start of treatment
Bev & 19k
Bev & Ang
Bev & Buffer
Bev & Endo
PBS & 19k
PBS & Ang
PBS & Buffer
PBS & Endo

FIGURE 7



Primary
Tumor volume (mm³)
300
250
200
150
100
50
0
Day 07
Day 14
Day 21
0
10
20
30
40
50
60
Day after start of treatment
Secondary
Tumor volume (mm³)
300
250
200
150
100
50
0
Day 07
Day 14
Day 21
0
10
20
30
40
50
60
Day after start of treatment

FIGURE 8

FIGURE 8A




FIGURE 8B




FIGURE 8 (CONTD.)

FIGURE 8C




FIGURE 8D




FIGURE 9

Treatment Group	Cure Rate (%)	
PBS (n=17)	1/17 (5.9%)	p < 0.001
TAV-Δ19K (n=18)	13/18 (72.2%)	
Bev (n=14)	0/14 (0%)	p < 0.001
Bev + TAV-Δ19K (n=17)	16/17 (94.1%)	